» Articles » PMID: 28948627

Prevalence of Exon 11 Internal Tandem Duplications in the C-KIT Proto-oncogene in Australian Canine Mast Cell Tumours

Overview
Journal Aust Vet J
Date 2017 Sep 27
PMID 28948627
Citations 8
Authors
Affiliations
Soon will be listed here.
Abstract

Objective: To measure the prevalence of internal tandem duplications (ITDs) in exon 11 of the proto-oncogene C-KIT in a sample of Australian cutaneous canine mast cell tumours (MCTs) drawn from general practice and to evaluate relationships between tumour mutation status and prognostic factors including signalment, tumour histological grade, tumour anatomical location and tumour size.

Methods: C-KIT exon 11 ITDs were detected by PCR in DNA extracted from formalin-fixed, paraffin-embedded canine MCTs sourced from three veterinary diagnostic laboratories in Adelaide and Melbourne. Tumours were graded according to two different systems (Patnaik and Kiupel systems) by board-certified anatomical pathologists blinded to the PCR results. Relationships between tumour mutation status and prognostic factors were evaluated using a generalised binary logistic regression analysis.

Results: ITDs were identified in 13 of 74 cutaneous canine MCT samples, giving an overall prevalence of 17.6% (95% confidence interval: 8.9-26.2%). ITDs were detected in 10 of 18 Patnaik grade III MCTs (55.6%) and 11 of 22 Kiupel high-grade MCTs (50%). Wald chi-square analysis revealed that detection of tumour ITDs was significantly associated with both Patnaik's and Kiupel's histologic grading systems (each: P < 0.001). The presence of the ITDs in MCTs was not associated with signalment, tumour anatomical location or tumour size.

Conclusion: The prevalence of C-KIT exon 11 ITDs in Australian canine MCTs is similar to the prevalence in overseas canine populations (overall prevalence in Australia approximately 18%). ITDs were more frequently identified in higher grade MCTs.

Citing Articles

Mutational Landscape of Proto-Oncogene Coding Sequence in 62 Canine Cutaneous and Subcutaneous Mast Cell Tumors.

Montanucci L, Guidolin E, Lopparelli R, Mucignat G, Pauletto M, Giantin M Vet Sci. 2024; 11(12).

PMID: 39728933 PMC: 11680137. DOI: 10.3390/vetsci11120593.


Artificial intelligence can be trained to predict -11 mutational status of canine mast cell tumors from hematoxylin and eosin-stained histological slides.

Puget C, Ganz J, Ostermaier J, Conrad T, Parlak E, Bertram C Vet Pathol. 2024; 62(2):152-160.

PMID: 39422217 PMC: 11874474. DOI: 10.1177/03009858241286806.


Clinical Use of Molecular Biomarkers in Canine and Feline Oncology: Current and Future.

Aupperle-Lellbach H, Kehl A, de Brot S, van der Weyden L Vet Sci. 2024; 11(5).

PMID: 38787171 PMC: 11126050. DOI: 10.3390/vetsci11050199.


Treatment of multiple synchronous canine mast cell tumours using intratumoural tigilanol tiglate.

Brown G, Finlay J, Straw R, Ziea J, Leung B, OConnell K Front Vet Sci. 2022; 9:1003165.

PMID: 36387404 PMC: 9643212. DOI: 10.3389/fvets.2022.1003165.


Mutations in Exons 8 and 11 of Gene in Canine Subcutaneous Mast Cell Tumors and Their Association with Cell Proliferation.

Chen P, Marconato L, Sabattini S, Kiupel M Vet Sci. 2022; 9(9).

PMID: 36136708 PMC: 9501132. DOI: 10.3390/vetsci9090493.